The study will enroll 500 consumers and 500 healthcare providers. The FDA will analyze their perceptions about certain fictional drug names for high cholesterol and gastroesophageal reflux disease.
For both conditions, participants will be presented with seven fictional drug names. Five will be names that may suggest the medical condition the drug is designed to treat and vary in terms of promise of effect. One will be a name that explicitly suggests efficacy or extreme value (the FDA provided “CureFlux” as an example), and one will be a neutral name.
Participants will answer questions about the names before and after the researchers tell them the drugs’ indications.
More articles on pharmacy:
Gilead, Merck co-developing long-acting HIV treatment
Roche to buy COVID-19 test maker for $1.8B
No link between AstraZeneca vaccine, blood clots, WHO says, despite countries halting use
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
